ArticleHuman vaccines & immunotherapeutics2025
Trends and determinants of 23-valent pneumococcal polysaccharide vaccine revaccination among older adults in Shanghai, China, 2013-2023: A database-based study.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pneumococcal disease remains a significant public health concern among older adults in China. The 23-valent pneumococcal polysaccharide vaccine (PPV23) has been shown to reduce the incidence of pneumococcal diseases, and timely revaccination helps maintain high levels of protective antibodies. However, data on PPV23 revaccination practices in this population remain limited. This study analyzed vaccination records from Shanghai's Immunization Program Information System (2013-2023) to evaluate PPV23 revaccination rates, temporal trends, and associated determinants (gender, household registration, residence, type of first dose, other vaccination history) among older adults. Joinpoint regression assessed temporal trends, while a 1:1 matched case-control analysis with conditional logistic regression and restricted cubic splines identified determinants. Among 136,454 eligible individuals, the overall revaccination rate was low (4.3%). Rates declined with increasing age in successive birth cohorts. From 2018 to 2023, annual revaccination rates showed a non-significant downward trend (APC = -15.9, 95% CI: -38.1-14.2). Multivariable analysis identified three determinants independently associated with PPV23 revaccination. Both urban residency (adjusted OR = 6.43, 95% CI: 5.54-7.46) and prior influenza vaccination (adjusted OR = 9.09, 95% CI: 7.91-10.45) were strongly associated with higher revaccination odds. Conversely, COVID-19 vaccination (adjusted OR = 0.19, 95% CI: 0.14-0.26) were associated with substantially lower revaccination odds. These findings highlight the generally low PPV23 revaccination coverage among older adults in Shanghai, particularly among suburban residents, and individuals without a history of influenza vaccination. Public health strategies should prioritize education - particularly in suburban areas - and integrate PPV23 with influenza vaccination programs to enhance uptake and mitigate pneumococcal disease burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.